Hamilton Thorne receives FDA clearance for Multi-Pulse software

Hamilton Thorne’s (TSX-V:HTL) Multi-Pulse software has received FDA clearance for performing embryo biopsy in clinical settings. The software will come standard with Hamilton Thorne’s best-in-class LYKOS clinical laser system and as an option on the legacy ZILOS-tk system in certain markets. The Multi-Pulse feature provides rapid, repeated firing of the laser to facilitate removal of [...]

Amorfix to collaborate with world leader in prions

Amorfix Life Sciences (TSX:AMF) has agreed to collaborate with Dr. Detlev Riesner, a world leader in prion diagnostics, using Amorfix’s proprietary prion antibody in a promising new blood test for animal prion infection. The scientific group of Dr. Riesner at Germany’s Heinrich-Heine-University has published in PLoS ONE, a prototype assay sensitive to the extremely low [...]

Navidea at two Alzheimer’s scientific meetings

Dr. Thomas Tulip, EVP and CBO of Navidea Biopharmaceuticals (AMEX:NAVB), was invited to present at two Alzheimer’s disease conferences: Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board meeting in New Orleans and the German Nuclear Medicine Convention in Bremen. Focused on Navidea’s AZD4694 radiopharmaceutical imaging biomarker for the detection of cerebral amyloid in Alzheimer’s [...]

MediciNova gets notice of Australian patent

MediciNova (NASDAQ:MNOV; OSE:4875) has received a notice of allowance from the Australian Government Patent Office for a pending patent application that covers the use of ibudilast (MN-166) for the treatment of multiple forms of chronic neuropathic pain. The allowance of these claims in Australia complements MediciNova-owned patent rights for methods of treating existing chronic neuropathic [...]

BIOTECanada head stepping down; search for successor launched

After seven years at the helm, BIOTECanada’s popular president and CEO Peter Brenders is stepping down in early May. As a result, the association’s board has initiated a search for Mr. Brenders’ successor.  More information on the search can be accessed here. Mr. Brenders, who is joining Genzyme Canada as general manager on May 7, [...]

OncoSec posts positive interim Phase 4 data

OncoSec Medical Inc. (OTCBB:ONCS) has reported positive interim analysis of data from 81 subjects in a Phase 4 study of primary and locally recurrent squamous cell carcinoma of the head and neck treated with OMS ElectroChemotherapy in Europe. The study demonstrated the therapy’s ability to provide local tumor control and quality of life outcomes that [...]

GeneNews announces rights offering

GeneNews (TSX:GEN) will offer shareholders of record May 1, 2012, one right for each common share held, with four rights entitling the holder to purchase one additional common share at a price of 11 cents. A fully subscribed rights offering will raise gross proceeds of about $2,554,700, which will be used to support commercialization of [...]

NovaBay to present new case studies on NeutroPhase

NovaBay  Pharmaceuticals (AMEX:NBY) will present new case studies using NeutroPhase, its pure hypochlorous acid wound cleanser, at the 2012 Spring Symposium on Advanced Wound Care  in Atlanta  on April 19 to 22. Dr. John Crew, medical director of the San Francisco Center for Advanced Wound Care at the Seton Medical Center, will present his case study [...]

Roth assigns new buy rating to NovaBay

Roth Capital Partners has re-established its estimates and assigned a Buy rating and $3.50 price target for NovaBay Pharmaceuticals (AMEX: NBY). “We view NBY shares as undervalued based on our sum-of-the-parts DCF analysis,” writes analyst Yale Jen, Ph.D. “We believe potential rapid maturation of the product pipeline in multiple Phase III studies represents upside potential [...]

Novadaq underwriters exercise over-allotment

Prior to the closing of a public offering of 6.1 million common shares at $5.75 a piece, underwriters for Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) exercised in full an option to purchase an additional 915,000 common shares at the same price solely to cover overallotments. After deducting commissions and other expenses, Novadaq received net proceeds of about [...]

« Previous Page — Next Page »